Indeed, different PARP1 inhibitors have demonstrated atheroprotective effects by decreasing PARP activation, inflammatory markers, macrophage recruitment, endothelial dysfunction, foam cell death thus promoting plaque stability (88). This evidence concerns the gene PARP1 and endothelial dysfunction.